IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Adenine Used as Agent Induced of Chronic Kidney Disease Accompanied Anemia for Rats and rHuEPO-alpha on MgO Nanoparrticles as Drug Delivery 'in vivo study'

Author: AMEER SULTAN, ASMA HADI MOHAMMED, FATIN FADHEL MOHAMMED AL-KAZAZ, SHAIMAA HAMED JABER
Abstract: Objective: Tagging Magnesium Oxide nanoparticle to rHuEPO-alpha for investigation the MgO NPS impact on erythropoietin hormone levels in sera and on kidneyes ? tissue of rats with anemia accompanied kidney disease CKD,trying to improve the level of hemoglobin in the blood. Methods: Magnesium Oxide nanoparticles were prepared by the co-precipitate method and then investigated by X-ray diffraction and Transmission Electron Microscopy. The study of toxicity was done for thirty male rats. After occurrence of chronic renal failure associated with anemia for sixty two rats which were divided into three groups : 22 rats treatment with magnesium oxide nanoparticle ,20rats treatment with rHuEPO-alpha and 20 rats treatment with magnesium oxide nanoparticle tagged with rHuEPO-alpha furthermore the fourth group(control) consist of 22 male rats. Results: The average crystallite size of magnesium oxide nanoparticle was about 10 nm. All rats survived without any symptoms of toxicity under acertin dose , indicating the safety of magnesium oxide subcutaneously dose for 28 days at 10000 µg.mL-1. The results showed a highly significant (p= 0.01 ) decrease in the levels of serum urea and serum creatinine, and a highly significant increase in the levels of blood hemoglobin and serum erythropoietin in rats groups of subcutaneous administration of (MgO NPs binbing with rHuEPO-alpha ) compared with rats administration of oral adenine groups(rats with anemia associated with Chronic kidney disease). Conclusion: Magnesium oxide nanoparticles may exhibit an effect on increasing the effeciency of rHuEPO-alpha , furthermore improvement the binding and interaction between the hormone EPO and its receptor, then elevated the concentration and effeciency of EPO hormone in the blood then increasing hemoglobin synthesis, therefore, reduced the anemia state. To the best of our knowledge, this is the first study has done demonstrated the impact of tagged MgO NPs with rHuEPO-alpha treatment on rats with anemia accompanied by CKD.
Keyword: MgONPs binding with rHuEPO-alpha , XRD, TEM ,Toxicity of MgONPs, Adenine, Anemia,CKD.
DOI: https://doi.org/10.31838/ijpr/2021.13.01.035
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free